Autism research leads to start-up
A new company spun out of Deakin and The Florey Institute of Neuroscience and Mental Health will explore the potential of promising new autism treatments.
Autism Spectrum Disorder (ASD) is one of the most significant neurological conditions affecting children and their families, with approximately one in 100 people diagnosed with the disorder.
While ASD is not well served by currently available medications, a new start-up company is developing novel medicines for the condition, based on innovative research from Deakin University and The Florey Institute.
